Trial Profile
A retrospective, observational study to assess clinical effectiveness of Gla-300 in a cohort of UK patients with type 1 diabetes (T1D)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SPARTA
- 25 Oct 2018 Results published in the Diabetic Medicine
- 24 Apr 2018 New trial record
- 20 Mar 2018 Primary endpoint has been met. (Change in HbA1c levels from baseline to Month 6 after the initiation of Gla-300) as per result presented at The 100th Annual Meeting of the Endocrine Society